NFKB1 and Alzheimer disease: 2003; Glass et al. 2010; Zotova et al. 2010). Therefore, decreasing neuroinflammation could be an alternative strategy in AD drug discovery. NF-κB is a crucial transcriptional regulator of inflammatory response including brain. Accumulating evidences reveal that NF-κB signalling in neurons, microglia and astrocytes forms a vicious cascade of inflammatory events in mediating neuronal loss in AD (Mattson & Camandola 2001).